MarketCap
Facebook
X
Telegram
Affimed N.V. ROCE Ratio | AFMD
Annual ROCE Ratio Affimed N.V.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -149.7 | -53.13 | -39.87 | -31.94 | -41.95 | -24.63 | -63.41 | -75.63 | -30.33 | -22.91 | - | - | - |
Annual performance
Select metrics to display
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -22.91 | -149.7 | -53.35 |
Quarterly ROCE Ratio Affimed N.V.
| 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -229.73 | -227.0 | -77.3 | -86.81 | -59.75 | -59.75 | -91.69 | -81.32 | -97.76 | -57.88 | -99.83 | -90.32 | -103.67 | -71.73 | -96.36 | -79.92 | -99.24 | -57.29 | -120.7 | -107.35 | -182.99 | -158.36 | -190.09 | -170.77 | -63.41 | - | - | - | -75.63 | - | - | - | -31.73 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -31.73 | -229.73 | -106.24 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Innate Pharma S.A.
IPHA
|
-207.17 | $ 1.54 | 1.98 % | $ 138 M |  France |
 |
Seneca Biopharma, Inc.
SNCA
|
-108.46 | - | -1.19 % | $ 28.7 M |  USA |
 |
BioMarin Pharmaceutical
BMRN
|
5.99 | $ 57.1 | -0.14 % | $ 11 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
-121.15 | $ 1.19 | -4.03 % | $ 6.51 M | USA |
 |
Enanta Pharmaceuticals
ENTA
|
-131.88 | $ 11.24 | -2.01 % | $ 240 K | USA |
 |
SIGA Technologies
SIGA
|
11.76 | $ 3.14 | -3.83 % | $ 225 M | USA |
 |
Milestone Pharmaceuticals
MIST
|
-148.77 | $ 0.68 | -7.49 % | $ 72.2 M |  Canada |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
12.37 | $ 94.9 | -3.91 % | $ 7.04 B | USA |
 |
Lipocine
LPCN
|
-71.64 | $ 1.59 | -7.85 % | $ 8.66 M | USA |
 |
PTC Therapeutics
PTCT
|
44.91 | $ 64.12 | -1.4 % | $ 5.1 B | USA |
 |
Seres Therapeutics
MCRB
|
-79.05 | $ 1.55 | -8.75 % | $ 13.7 M | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
-31.61 | $ 432.48 | -0.07 % | $ 9.7 B | USA |
 |
CEL-SCI Corporation
CVM
|
-155.48 | $ 1.41 | 4.07 % | $ 11.3 M | USA |
 |
Inventiva S.A.
IVA
|
5530.5 | $ 3.95 | 2.73 % | $ 236 M | France |
 |
MeiraGTx Holdings plc
MGTX
|
1829.24 | $ 9.62 | 1.37 % | $ 774 M | USA |
 |
Processa Pharmaceuticals
PCSA
|
-250.81 | $ 1.86 | -4.62 % | $ 2.44 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-1.57 | $ 67.5 | 4.9 % | $ 1.82 B | USA |
 |
IDEAYA Biosciences
IDYA
|
-15.17 | $ 31.72 | -0.97 % | $ 2.81 B | USA |
 |
Protalix BioTherapeutics
PLX
|
-9.85 | $ 2.86 | 11.28 % | $ 225 M |  Israel |
 |
Lantern Pharma
LTRN
|
-275.14 | $ 0.47 | -22.86 % | $ 5.12 M | USA |
 |
Foghorn Therapeutics
FHTX
|
-62.44 | $ 1.89 | -7.35 % | $ 119 M | USA |
 |
Ocugen
OCGN
|
-307.31 | $ 0.95 | -2.45 % | $ 297 M | USA |
 |
Oncolytics Biotech
ONCY
|
-584.69 | $ 0.38 | -5.64 % | $ 36.4 M | Canada |
 |
Minerva Neurosciences
NERV
|
-16.65 | $ 2.47 | -6.08 % | $ 20.9 M | USA |
 |
Kamada Ltd.
KMDA
|
7.92 | $ 8.09 | 4.93 % | $ 466 M | Israel |
 |
Neurocrine Biosciences
NBIX
|
15.92 | $ 169.08 | 0.13 % | $ 16.8 B | USA |
 |
Nanobiotix S.A.
NBTX
|
-105.52 | $ 32.8 | 2.4 % | $ 1.57 T | France |
 |
Mereo BioPharma Group plc
MREO
|
-68.72 | $ 0.3 | 1.66 % | $ 239 M |  Britain |
 |
Maravai LifeSciences Holdings
MRVI
|
-38.08 | $ 7.86 | -2.31 % | $ 1.13 B | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
-29.8 | $ 1.84 | 0.82 % | $ 668 M | USA |
 |
Moleculin Biotech
MBRX
|
-167.29 | $ 8.01 | -7.51 % | $ 9.49 M | USA |
 |
Nurix Therapeutics
NRIX
|
-53.02 | $ 15.89 | -1.58 % | $ 1.38 B | USA |
 |
Nkarta
NKTX
|
-31.94 | $ 1.36 | -14.78 % | $ 101 M | USA |
 |
MacroGenics
MGNX
|
-131.03 | $ 2.42 | 3.42 % | $ 153 M | USA |
 |
Protagonist Therapeutics
PTGX
|
-25.39 | $ 136.18 | 0.2 % | $ 8.66 B | USA |
|
Nuvation Bio
NUVB
|
-41.57 | $ 4.22 | -3.1 % | $ 1.44 B | USA |
 |
Novo Nordisk A/S
NVO
|
39.01 | $ 40.6 | -1.88 % | $ 180 B |  Danmark |
 |
Marker Therapeutics
MRKR
|
-76.74 | $ 0.95 | -3.87 % | $ 14.5 M | USA |
 |
NextCure
NXTC
|
-93.13 | $ 5.97 | -4.78 % | $ 17 M | USA |
 |
Rocket Pharmaceuticals
RCKT
|
-83.6 | $ 2.46 | -2.96 % | $ 273 M | USA |
 |
PMV Pharmaceuticals
PMVP
|
-81.99 | $ 1.22 | -2.8 % | $ 64.1 M | USA |
 |
Olema Pharmaceuticals
OLMA
|
-37.1 | $ 7.29 | -1.02 % | $ 634 M | USA |
 |
Kymera Therapeutics
KYMR
|
-21.05 | $ 136.45 | -1.74 % | $ 11.5 B | USA |
 |
Oragenics
OGEN
|
-113.05 | $ 0.35 | -1.47 % | $ 755 K | USA |
 |
Ovid Therapeutics
OVID
|
-29.75 | $ 2.8 | -1.75 % | $ 365 M | USA |
 |
Passage Bio
PASG
|
-185.64 | $ 3.81 | 11.08 % | $ 12.2 M | USA |
 |
Vaxcyte
PCVX
|
-33.02 | $ 66.44 | -1.61 % | $ 9.04 B | USA |
 |
Relay Therapeutics
RLAY
|
-50.82 | $ 19.81 | -2.87 % | $ 3.4 B | USA |
 |
Precigen
PGEN
|
-93.49 | $ 4.51 | -4.76 % | $ 1.41 B | USA |
 |
Avidity Biosciences
RNA
|
-44.18 | $ 8.23 | -1.79 % | $ 1.13 B | USA |